AI is accelerating drug discovery and compressing the timeline for critical intellectual property decisions. This article explores how biotech and pharmaceutical companies can build stronger patent strategies, documentation practices, and decision frameworks to protect innovation and long-term enterprise value.

Early-stage IP decisions in life sciences often occur under pressure but carry long-term implications for licensing, valuation, and portfolio flexibility. This article explores how early patent strategy shapes commercialization outcomes.